Hallo! Tracked shipping to Netherlands with Delivery Duty Paid for just €7 

Ship to
Netherlands
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada Epidemiology of Ranibizumab Intravitreal Applications: Analysis of Intravitreal Applications of Ranibizumab for the Visually Impaired
Type
Physical Book
Publisher
Author
Language
English
Format
Paperback
ISBN13
9786207781904

Epidemiology of Ranibizumab Intravitreal Applications: Analysis of Intravitreal Applications of Ranibizumab for the Visually Impaired

Gabriela Dos Santos Souza Barros; Alléxya A. A. Marcos; Gabriella M.g. Nogueira (Author) · Ks Omniscriptum Publishing · Paperback

Epidemiology of Ranibizumab Intravitreal Applications: Analysis of Intravitreal Applications of Ranibizumab for the Visually Impaired - Gabriela Dos Santos Souza Barros; Alléxya A. A. Marcos; Gabriella M.G. Nogueira

Cheaper New Book Imported to Netherlands
Delivery: 27 Aug - 01 Sep Shipping: 14 to 15 business days.
€ 44,45
Faster New Book Imported to Netherlands
Delivery: 14 Aug - 18 Aug Shipping: 5 to 6 business days.
€ 47,00
Import costs and 9% BTW included in the price ✅
€ 44,45

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "Epidemiology of Ranibizumab Intravitreal Applications: Analysis of Intravitreal Applications of Ranibizumab for the Visually Impaired"

The use of intravitreal anti-VEGF is becoming increasingly routine in ophthalmological practice today and is responsible for the treatment of numerous ocular pathologies. It basically acts by inhibiting the angiogenesis that this endothelial growth factor promotes. Studies show that VEGF-A is the factor that most induces vascular permeability and is therefore involved in the genesis of ocular neovascularisation, present in diseases such as AMD, diabetic retinopathy, vascular occlusions, among others. There are numerous drugs that are currently used to treat the aforementioned pathologies. These include Pegaptanib (MacugenR), which basically inhibits forms of VEGF longer than 165 amino acids. Bevacizumab, which is a humanised monoclonal antibody (AvastinR), acts directly against VEGF-A and all its isoforms, but its ocular use is off-label.2 Ranibizumab (LucentisR) acts by inhibiting all isoforms of VEGF-A, and because it is a humanised antibody fragment, it easily penetrates the retina.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews